Quick Answer
PharmaCyte Biotech, Inc. reported Operating Income Loss of -$4.38 million for the year ending 2025.
- PharmaCyte Biotech, Inc. showed an increase of +48.6% in Operating Income Loss from 2024 to 2025.
- This data is from PharmaCyte Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on August 11, 2025.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), PharmaCyte Biotech, Inc.'s Operating Income Loss has declined by 124.6%.
- Historical annual values: Fiscal year 2025: -$4.38 million | Fiscal year 2024: -$8.52 million | Fiscal year 2023: -$6.46 million | Fiscal year 2022: -$4.39 million | Fiscal year 2021: -$3.62 million | Fiscal year 2020: -$3.83 million | Fiscal year 2019: -$4.10 million | Fiscal year 2018: -$6.98 million | Fiscal year 2017: -$4.44 million | Fiscal year 2016: -$6.07 million | Fiscal year 2015: -$13.26 million | Fiscal year 2014: -$18.98 million | Fiscal year 2013: -$1.68 million | Fiscal year 2012: -$1.95 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: